United Therapeutics (UTHR, Financial) has reported a notable first quarter revenue of $794.4 million, surpassing market expectations which stood at $726.36 million. CEO Martine Rothblatt highlighted the strong start to 2025 with this record-breaking revenue. The company plans to maintain its momentum through the year by advancing its innovative projects, including the TETON 2 study for idiopathic pulmonary fibrosis and initiating the UKidney clinical study. Additionally, there are plans to file investigational new drug applications with the FDA for UHeart and UThymoKidney, aimed at developing an unlimited supply of transplantable organ alternatives.
COO Michael Benkowitz credited the commercial team's strategic execution for the impressive revenue achievement, emphasizing the company's strengthened position in the pulmonary hypertension sector. The focus remains on expanding United Therapeutics' presence as the preferred choice for prostacyclin products, with a commitment to building on this success throughout the year.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for United Therapeutics Corp (UTHR, Financial) is $391.02 with a high estimate of $600.00 and a low estimate of $314.00. The average target implies an upside of 30.01% from the current price of $300.76. More detailed estimate data can be found on the United Therapeutics Corp (UTHR) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, United Therapeutics Corp's (UTHR, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for United Therapeutics Corp (UTHR, Financial) in one year is $380.58, suggesting a upside of 26.54% from the current price of $300.76. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the United Therapeutics Corp (UTHR) Summary page.
UTHR Key Business Developments
Release Date: February 26, 2025
- Record Revenue Year: 2024 marked the third consecutive year of record-setting revenue for United Therapeutics.
- Overall Revenue Growth: Achieved almost 24% growth over the full year 2023.
- Fourth Quarter Revenue Growth: 20% increase from the fourth quarter of 2023.
- Tyvaso Revenue: $416 million for the fourth quarter, a 19% increase over the previous year.
- Orenitram Revenue: 28% growth in the fourth quarter of 2024 to $108 million.
- Remodulin Revenue: Fourth quarter worldwide revenue of $135 million, up 17% from the prior year period.
- Unituxin Revenue: Record revenue of $68 million for the fourth quarter, up 25% from the prior year quarter.
- Shareholder Returns: $1 billion returned through an accelerated share repurchase program.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- United Therapeutics Corp (UTHR, Financial) achieved a record revenue year in 2024, marking the third consecutive year of record-setting revenue.
- The company has initiated a groundbreaking kidney clinical trial, which could potentially eliminate the need for dialysis for patients with end-stage renal disease.
- Enrollment for the inhaled Treprostinil TETON 1 study in idiopathic pulmonary fibrosis has been completed, with promising top-line data expected in the coming years.
- The development of ralinepag as a once-daily oral prostacyclin antagonist for pulmonary arterial hypertension could significantly alter treatment paradigms and represents a multibillion-dollar opportunity.
- United Therapeutics Corp (UTHR) returned $1 billion to shareholders through an accelerated share repurchase program, demonstrating strong capital allocation and shareholder value focus.
Negative Points
- The company's fourth-quarter net revenue saw a slight sequential decline, attributed to recent contracting efforts for Tyvaso.
- There is uncertainty regarding the impact of potential competitors on Tyvaso's market position, despite efforts to secure payer contracts.
- The company does not provide specific sales guidance for 2025, leaving some uncertainty about future growth trajectories.
- The success of the kidney clinical trial and subsequent investments in additional facilities remain speculative and dependent on trial outcomes.
- The impact of new treatments like Windover on the PAH market could potentially affect the growth of Tyvaso, although the company remains optimistic about its positioning.
